Journal list Promote Sponsor
verified SJR 0,377 · Q3 • database Scopus / SJR & Web of Science indexed
Diagnostic Cytopathology
United States · John Wiley and Sons Inc
workspace_premium Q3 — Medicine (miscellaneous) lock_open Open Access

Diagnostic Cytopathology

Diagnostic Cytopathology is a journal indexed in SJR in Medicine (miscellaneous) and Pathology and Forensic Medicine with an H index of 75. It has a price of 2417 €. It has an SJR impact factor of 0,377 and it has a best quartile of Q3. It is published in English. It has an SJR impact factor of 0,377.

Diagnostic Cytopathology focuses its scope in these topics and keywords: aspiration, cytology, pap, test, fineneedle, cases, carcinosarcoma, intrahepatic, discrepancies, cytologytwo, ...

ISSN: 8755-1039
Publisher: John Wiley and Sons Inc
Category: Medicine (miscellaneous)
Indexation: verifiedScopus / SJR verifiedWeb of Science
open_in_new Portal NPD menu_book Guidelines NPD
schedule CountryOfPapers database fields
SJR Impact Factor trending_up
0,377 Q3
H-index 75
Acceptance rate pie_chart
28% Selective
Source Acceptance_Rate
Time to publication hourglass_top
NPD
Field NPD
Publication cost (APC) payments
2.417 € Open Access
Non-OA path 0 €

Metrics

Scimago and CountryOfPapers database fields

Scopus / SJR Web of Science

SJR Impact

0,377

H-index

75

Docs (year)

163

Docs 3y

619

Total refs

3525

Cites 3y

704

Citable 3y

560

Cites/Doc 2y

1.08

Ref/Doc

21.63

Immediate OA

2417 €

Embargoed OA

NPD

Non OA / Submission

0 €

shield Researcher voice

Name good journals. Call out predatory ones.

Share what peer review, fees, and timelines were really like. Praise fair editors. Flag APC traps, fake metrics, or spam solicitations — with facts from your submission.

Fair & fast peer review Clear APC / no surprise fees Suspected predatory Fake impact claims
rate_review Write an honest review

Researcher reviews

sentiment_dissatisfied No reviews yet — be the first to share an honest experience.
User
* Only to validate authenticity — identity is not shown publicly.

FAQs